Dissolution Testing For Inhaled drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dissolution Testing For Inhaled drugs
Although there are no regulatory requirements or established pharmacopoeial techniques for the dissolution testing of inhaled drugs, such testing can potentially open up the opportunity to tailor formulation properties. The authors explain how a new technique using standard dissolution test equipment in combination with US Pharmacopeia methods for the dissolution testing of solid dosage forms can be used to differentiate the solubility of orally inhaled products.


Pharmaceutical Technology Europe
Volume 22, Issue 11

Developing a dissolution testing technique for inhalable formulations

In 2003, Feddah and Davies introduced a dissolution testing technique for inhalable formulations based on a flow through apparatus.7 This technique involves the use of an Andersen cascade impactor (ACI) to capture the emitted dose from the DPI. A glass fibre filter mounted at the base of a USP induction port, of the type routinely used with multistage cascade impactors, captures the dose during otherwise standard operation of the ACI. Once captured, the dose is held in a dissolution cell through which solvent is pumped at a known flow rate.

This method was used to differentiate the solubility of glucocorticoids employed in the treatment of pulmonary disease, but it has a number of disadvantages. Firstly, although an ACI was used to capture the dose for testing, the size fractionation capabilities of the impactor were not exploited — the entire emitted dose was captured. Therefore, the recorded dissolution behaviour does not relate to just those particles fine enough to deposit in the lung. An additional problem is the amount of solvent used in flow through testing, which is significant; no attempt is made to simulate the sparing presence of lung surfactant in vivo. Furthermore, recorded solubility is dependent on the flow rate of solvent selected, making it too easy to achieve noncomparable results for "zero order" drug solubility.


Figure 1: NGI dissolution cup and membrane holder (Copley Scientific, UK).
To address these issues and improve test sensitivity, researchers at the University of Texas have developed a dissolution test for OIP formulations based on the standard "Paddle over Disc" method described in US Pharmacopeia Method 5 and European Pharmacopoeia 2.9.4.8,9 A modified version of this solution is now commercially available (Figure 1). To ensure analysis only of the portion of interest in the emitted dose, the apparatus enables preseparation and sample collection using a Next Generation Impactor (NGI), one of the systems of choice for routine aerodynamic particle size distribution (APSD) measurement.

Multistage cascade impactors, such as the NGI and ACI, separate the emitted dose from an OIP into fractions on the basis of aerodynamic particle size. Using the NGI, these fractions are captured in collection cups. The NGI dissolution cup (Copley Scientific, UK) is almost identical to a standard NGI cup except that it has a 50 mm removable insert in the impaction area where separated sample collects. It fits directly into positions 2 through 7 in a standard NGI cup tray.


Figure 2: NGI membrane holder in position in the vessel of a standard USP Method 2 test apparatus.
To collect a dose for dissolution testing the NGI is operated exactly as for routine APSD measurement, but with the dissolution cup installed at the stage of interest to allow capture of only the size fraction of interest rather than the entire emitted dose. Once collection is complete, the insert is simply removed from the cup and covered with a pre-punched 55 mm diameter polycarbonate membrane. Securing this in place with the supplied membrane holder forms a sealed disc or sandwich that can be placed in a vessel of a conventional dissolution tester (Figure 2). Dissolution testing can then be conducted in an exactly analogous way as for other solid dosage forms, using appropriate operating conditions.

Selection of an appropriate diffusion barrier for testing was crucial to the success of this solution. Although relatively thin (approximately 6 m), the polycarbonate membrane is robust with properties superior to those of a cellulose acetate alternative used in prototype studies. The chosen membrane neither swells nor creates air bubbles, and has non-tortuous cylindrical pores of well-defined size. These allow free diffusion of both the dissolved drug and dissolution media, enabling dissolution testing under relevant hydrodynamic conditions.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here